SCYNEXIS, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for SCYX, updated each market day.
SCYX AI Sentiment
AI sees no strong directional signal for SCYNEXIS, Inc. stock over the next 10 market days.
Prediction date: Sept. 22, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About SCYNEXIS, Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Sector
Exchange
Market Cap
$44,275,760
Cap Tier
Employees
29
Headquarters
JERSEY CITY, NJ
Listed Since
May 2, 2014
Website
SCYX Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SCYX Volatility
SCYNEXIS, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
